MA50245A - Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 - Google Patents
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2Info
- Publication number
- MA50245A MA50245A MA050245A MA50245A MA50245A MA 50245 A MA50245 A MA 50245A MA 050245 A MA050245 A MA 050245A MA 50245 A MA50245 A MA 50245A MA 50245 A MA50245 A MA 50245A
- Authority
- MA
- Morocco
- Prior art keywords
- octahydrocyclopenta
- shp2
- pyrrole
- allosteric inhibitors
- allosteric
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556713P | 2017-09-11 | 2017-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50245A true MA50245A (fr) | 2020-07-22 |
Family
ID=63794616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050245A MA50245A (fr) | 2017-09-11 | 2018-09-11 | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10435389B2 (fr) |
| EP (1) | EP3681879A1 (fr) |
| JP (2) | JP7447002B2 (fr) |
| CN (2) | CN111201223B (fr) |
| CA (1) | CA3074304A1 (fr) |
| MA (1) | MA50245A (fr) |
| TW (1) | TWI851542B (fr) |
| WO (1) | WO2019051469A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JP7044375B2 (ja) | 2016-05-31 | 2022-03-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｐｔｐｎ１１の複素環式阻害剤 |
| WO2018057884A1 (fr) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| WO2018218133A1 (fr) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2 |
| EP3687997A1 (fr) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Dérivés de pyrazolo[3,4-b]pyrazine utilisés en tant qu'inhibiteurs de la phosphatase shp2 |
| CA3094690A1 (fr) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Inhibiteurs de la phosphatase shp2 et leurs procedes d'utilisation |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| NZ770260A (en) | 2018-05-02 | 2024-12-20 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11 |
| KR102707409B1 (ko) | 2018-08-10 | 2024-09-13 | 나비레 파르마, 인코퍼레이티드 | 암 치료를 위한 ptpn11 (shp2) 저해제로서 6-(4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일)-3-(2,3-디클로로페닐)-2-메틸피리미딘-4(3h)-온 유도체 및 관련 화합물 |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| WO2020072656A1 (fr) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Dérivés d'imidozopyrimidine |
| PE20211465A1 (es) | 2018-10-17 | 2021-08-05 | Array Biopharma Inc | Inhibidores de la proteina tirosina fosfatasa |
| CA3130080A1 (fr) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Composes heteroaryle bicycliques et leurs utilisations |
| EP3930845A1 (fr) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Composés hétérocyclyle bicycliques et leurs utilisations |
| AU2020232026A1 (en) | 2019-03-07 | 2021-09-02 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as shp2 antagonists |
| GEP20237561B (en) | 2019-04-02 | 2023-10-25 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
| CN113646049B (zh) | 2019-04-08 | 2024-08-13 | 默克专利有限公司 | 作为shp2拮抗剂的嘧啶酮衍生物 |
| TW202126660A (zh) | 2019-09-24 | 2021-07-16 | 美商傳達治療有限公司 | Ｓｈｐ２磷酸酶抑制劑及其製備與使用方法 |
| PE20221278A1 (es) | 2019-11-04 | 2022-09-05 | Revolution Medicines Inc | Inhibidores de ras |
| CA3160142A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| EP4055017A1 (fr) | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Composés hétéroaryles bicycliques et leurs utilisations |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
| US20240051956A1 (en) | 2020-12-22 | 2024-02-15 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| EP4334324A1 (fr) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
| JP2024517845A (ja) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | がん治療のためのｒａｓ阻害剤 |
| CN114716448B (zh) * | 2021-05-13 | 2024-01-30 | 中国科学院上海药物研究所 | 抑制shp2活性的杂环化合物、其制备方法及用途 |
| WO2022259157A1 (fr) | 2021-06-09 | 2022-12-15 | Novartis Ag | Combinaison pharmaceutique triple comprenant du dabrafenib, du trametinib et un inhibiteur de shp2 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| JP2024532374A (ja) | 2021-09-01 | 2024-09-05 | ノバルティス アーゲー | Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2024206858A1 (fr) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions pour induire une hydrolyse de ras gtp et leurs utilisations |
| WO2024211663A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| WO2024211712A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (fr) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Polythérapie pour une maladie ou un trouble lié à ras |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP0647450A1 (fr) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Prodrogues améliorées pour activation médiée par enzyme |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| PT947513E (pt) * | 1996-10-25 | 2004-09-30 | Daiichi Seiyaku Co | Derivados de amina triciclicos |
| WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1085879A2 (fr) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Agents de liaison multiple, modulant le transporteur de 5-ht |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| NZ522783A (en) | 2000-06-28 | 2004-07-30 | Smithkline Beecham P | Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| RU2312861C2 (ru) | 2002-03-05 | 2007-12-20 | Мерк Фросст Кэнада Лтд. | Ингибиторы катепсин-цистеинпротеазы |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| MX2007002584A (es) | 2004-09-02 | 2007-09-07 | Genentech Inc | Inhibidores de piridilo de senalizacion de hedgehog. |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ES2537352T3 (es) | 2007-09-12 | 2015-06-05 | Genentech, Inc. | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso |
| CA2701292C (fr) | 2007-10-25 | 2015-03-24 | Genentech, Inc. | Procede de preparation de composes de thienopyrimidine |
| CN101538245B (zh) * | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| CN102292319A (zh) * | 2008-11-26 | 2011-12-21 | 雅培制药有限公司 | 作为钙通道阻滞剂的取代八氢环戊二烯并(c)吡咯-4-胺 |
| FR2945533B1 (fr) * | 2009-05-12 | 2011-05-27 | Sanofi Aventis | Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| EP2447263A1 (fr) * | 2010-09-27 | 2012-05-02 | Bioprojet | Dérivés de benzazole en tant que ligands du récepteur H4 |
| KR101271224B1 (ko) * | 2011-07-05 | 2013-06-10 | 한국과학기술연구원 | 항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법 |
| JP2014525452A (ja) * | 2011-08-29 | 2014-09-29 | ピーティーシー セラピューティクス， インコーポレイテッド | 抗菌化合物および使用方法 |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| EP3094627B1 (fr) * | 2014-01-17 | 2018-08-22 | Novartis AG | Dérivés de 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine et compositions les contenant pour l'inhibition de l'activité de shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (fr) | 2014-01-17 | 2015-07-23 | Novartis Ag | Dérivés de 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine et compositions les contenant pour l'inhibition de l'activité de shp2 |
| US10308660B2 (en) | 2015-06-19 | 2019-06-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| US10975080B2 (en) | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| EP3310774B1 (fr) | 2015-06-19 | 2020-04-29 | Novartis AG | Composés et compositions pour l'inhibition de l'activité de shp2 |
| WO2017156397A1 (fr) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Inhibiteurs hétérocycliques de ptpn11 |
| CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
| PL3464272T3 (pl) | 2016-06-07 | 2022-03-28 | Jacobio Pharmaceuticals Co., Ltd. | Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2 |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| KR20230156174A (ko) | 2016-07-12 | 2023-11-13 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| WO2018057884A1 (fr) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| EP4230623A3 (fr) | 2017-01-23 | 2023-10-11 | Revolution Medicines, Inc. | Composés de pyridine en tant qu'inhibiteurs allostériques de shp2 |
| TWI820013B (zh) | 2017-01-23 | 2023-11-01 | 美商銳新醫藥公司 | 作為別構ｓｈｐ２抑制劑之雙環化合物 |
| WO2018218133A1 (fr) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2 |
-
2018
- 2018-09-11 MA MA050245A patent/MA50245A/fr unknown
- 2018-09-11 CN CN201880058453.6A patent/CN111201223B/zh active Active
- 2018-09-11 JP JP2020536724A patent/JP7447002B2/ja active Active
- 2018-09-11 TW TW107131932A patent/TWI851542B/zh active
- 2018-09-11 WO PCT/US2018/050397 patent/WO2019051469A1/fr unknown
- 2018-09-11 EP EP18783183.9A patent/EP3681879A1/fr active Pending
- 2018-09-11 CN CN202410827042.6A patent/CN118684652A/zh active Pending
- 2018-09-11 US US16/127,772 patent/US10435389B2/en active Active
- 2018-09-11 CA CA3074304A patent/CA3074304A1/fr active Pending
-
2024
- 2024-02-28 JP JP2024028064A patent/JP2024059874A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3681879A1 (fr) | 2020-07-22 |
| CN111201223B (zh) | 2024-07-09 |
| WO2019051469A1 (fr) | 2019-03-14 |
| JP2020535218A (ja) | 2020-12-03 |
| CA3074304A1 (fr) | 2019-03-14 |
| US20190077792A1 (en) | 2019-03-14 |
| TW201912639A (zh) | 2019-04-01 |
| JP7447002B2 (ja) | 2024-03-11 |
| CN118684652A (zh) | 2024-09-24 |
| JP2024059874A (ja) | 2024-05-01 |
| US10435389B2 (en) | 2019-10-08 |
| CN111201223A (zh) | 2020-05-26 |
| TWI851542B (zh) | 2024-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50245A (fr) | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 | |
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP3898592C0 (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| EP3898616C0 (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
| IL269196A (en) | Novel inhibitors | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| EP3630783A4 (fr) | Inhibiteurs protéiques de liaison à la pénicilline | |
| EP3630782A4 (fr) | Inhibiteurs de protéines de liaison à la pénicilline | |
| EP3761992A4 (fr) | Inhibiteurs d'arginase | |
| MA53287A (fr) | Inhibiteurs de prmt5 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| MA53491A (fr) | Inhibiteurs de sarcomes cardiaques | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3609882A4 (fr) | Inhibiteurs hétérocycliques de pcsk9 | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| EP3712287A4 (fr) | Composant traité par nitration | |
| EP4051688A4 (fr) | Inhibiteurs de cd73 | |
| IL275195A (en) | History of pyrrole as ACC inhibitors | |
| EP3706742A4 (fr) | Inhibiteurs de prmt5 |